All In Biotech

Drug Trial Radar · NCT07801820

Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

A Randomized, Double-Blind, Placebo- and Active-Controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

240

Planned (sponsor's estimate)

Start

Jun 23, 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Sponsor type
Industry
First posted
Sep 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo- and active-controlled, multicenter Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of MWN109 tablets in participants with type 2 diabetes mellitus (T2DM). Eligible participants will be randomized to receive different dose levels of MWN109 tablets, MWN109-matched placebo, or semaglutide tablets 14 mg (active control), administered once daily for 20 consecutive weeks. Approximately 240 adults aged 18 to 75 years with type 2 diabetes mellitus will be enrolled. The primary endpoint is the percent change from baseline in HbA1c at Week 20. Secondary endpoints include glycemic parameters, body weight, metabolic parameters, adverse events, and immunogenicity.

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Interventions

  • MWN109 1Drug

    Administered orally, QD, 20 weeks

  • MWN109 2Drug

    Administered orally, QD, 20 weeks

  • MWN109 3Drug

    Administered orally, QD, 20 weeks

  • MWN109 4Drug

    Administered orally, QD, 20 weeks

  • PlaceboDrug

    Administered orally, QD, 20 weeks

  • Semaglutide TabletsDrug

    Administered orally, QD, 20 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Glycated Hemoglobin (HbA1c) from Baseline at Week 20 Compared to PlaceboTime frame: Baseline, Week 20

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.